Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Treatment of cowpox virus respiratory infections in mice with ribavirin asa single agent or followed sequentially by cidofovir
Autore:
Smee, DF; Bailey, KW; Sidwell, RW;
Indirizzi:
Utah State Univ, Dept Anim Dairy & Vet Sci, Inst Antiviral Res, Logan, UT 84322 USA Utah State Univ Logan UT USA 84322 nst Antiviral Res, Logan, UT 84322 USA
Titolo Testata:
ANTIVIRAL CHEMISTRY & CHEMOTHERAPY
fascicolo: 4, volume: 11, anno: 2000,
pagine: 303 - 309
SICI:
0956-3202(200007)11:4<303:TOCVRI>2.0.ZU;2-B
Fonte:
ISI
Lingua:
ENG
Soggetto:
1-BETA-D-RIBOFURANOSYL-1,2,4-TRIAZOLE-3-CARBOXAMIDE VIRAZOLE; HEPATITIS; ICN-1229; SAFETY;
Keywords:
antiviral; ribavirin; cidofovir; cowpox virus; bioterrorism;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Life Sciences
Citazioni:
21
Recensione:
Indirizzi per estratti:
Indirizzo: Smee, DF Utah State Univ, Dept Anim Dairy & Vet Sci, Inst Antiviral Res, Logan, UT 84322 USA Utah State Univ Logan UT USA 84322 iral Res, Logan, UT 84322 USA
Citazione:
D.F. Smee et al., "Treatment of cowpox virus respiratory infections in mice with ribavirin asa single agent or followed sequentially by cidofovir", ANTIVIR CHE, 11(4), 2000, pp. 303-309

Abstract

To better understand the potential of ribavirin in the treatment of orthopoxvirus infections (such as those acquired through bioterrorist activities), the efficacy of the drug was studied in a cowpox respiratory infection model in mice under varying disease severity. Mice did not survive a high intranasal cowpox virus challenge [3x10(6) plaque forming units (pfu)/animal] treated with subcutaneous ribavirin (100 mg/kg/day for 5 days), but lived 3.9 days longer than placebos. In contrast, 100% of animals receiving the same dose of drug survived a 3x10(5) pfu challenge compared with 0% survival of those that received placebo. Survival rates of 50 and 30% occurred with ribavirin doses of 50 and 25 mg/kg/day, respectively. At the 100 mg/kg/day dose, ribavirin reduced lung virus titres 40-fold on day 6 of the infectionrelative to titres in the placebo group. Weight loss resulting from illness and mean lung weights of mice treated with ribavirin were also significantly reduced. Mice were infected intranasally with the high 3x10(6) pfu virus challenge dose and treated with 100 mg/kg/day ribavirin for 5 days, followed by single injections of 75 mg/kg cidofovir on day 6, 7, 8 or 9. Cidofovir alone (without ribavirin) administered on day 6 had no beneficial effecton disease outcome. Ribavirin alone increased the mean time to death by 3.7 days. Ribavirin treatment for 5 days followed by cidofovir treatment on days 6 and 7 significantly increased the mean time to death beyond that achieved with ribavirin alone by 8.2 and 4.4 days, respectively, with 30 and 40% of mice surviving the infection. These results suggest that many individuals infected with an orthopoxvirus by aerosol route would benefit by a course of ribavirin therapy. Later, the fewer number of very sick individuals could be treated with intravenous cidofovir.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 03/07/20 alle ore 00:18:10